| Raising the bar for lower-risk myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations |
|
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
|
American Journal of Hematology |
Aplastic Anemia |
| An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery? |
|
Leukemia & Lymphoma |
Aplastic Anemia |
| Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Therapy-related myelodysplastic syndromes in the genomics era |
|
Bulletin du Cancer |
Myelodysplastic Syndromes (MDS) |
| Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction |
|
SAGE Open Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
